SDG’s seminal work in the life sciences industry is widely recognized as having helped create billions of dollars in shareholder value and having transformed the way R&D and portfolio investment decisions are evaluated and implemented. The frameworks developed by SDG for portfolio prioritization are now accepted as best practice in the life sciences industry.
SDG provides strategy and advisory services to pharmaceutical, biotech, medical device and diagnostics clients worldwide. We work together with these clients to develop growth strategy, portfolio management, and M&A and due diligence advisory services. Our consultants understand the rapidly evolving Asia-Pacific pharmaceutical landscape through our experience supporting clients as they develop market entry and access strategies in key markets such as China, Korea, India and Indonesia.
In addition, many of our clients look to SDG's education and training services to develop analytical staff within internal portfolio management and decision support units.